Charles River Laboratories SEC filings, summarized
We read every Charles River Laboratories 8-K filing and insider trade the night it hits SEC EDGAR, and turn it into a two-minute plain-English summary.
Track CRL in your inbox
Add Charles River Laboratories to your watchlist — free, every morning.
Recent filings
Charles River reaffirms 2026 outlook and sets 2030 growth targets
At its September 24, 2026 Investor Day, Charles River Laboratories reaffirmed its 2026 guidance, expecting revenue and non-GAAP EPS at the upper ends of…
Charles River Laboratories director James Foster sells $10.1M in stock
James C. Foster, a director of Charles River Laboratories International, sold 33,561 shares of common stock on the open market at $300.00 per share, for…
Charles River CEO Birgit Girshick sells $1.8M in stock
Birgit Girshick, Chief Executive Officer and director of Charles River Laboratories, sold 6,500 shares in an open-market transaction at $279.90 per share on…
Charles River CEVP Shannon Parisotto sells $1.04M in stock
Shannon M. Parisotto, CEVP, Discovery and Safety Assessment at Charles River Laboratories International, sold 3,714 shares of common stock on Aug. 11 at…
Charles River director James Foster sells $7.9M in stock
James C. Foster, a director of Charles River Laboratories International, sold 28,733 shares of common stock on Aug. 10 at $275.00 per share, for an…
Charles River Labs SVP sells about $1.7M in stock
Michael Gunnar Knell, SVP, Finance and CAO of Charles River Laboratories, sold 6,645 shares in nine open-market transactions on Aug. 6 at prices ranging…
Charles River Labs EVP sells $1.08M in stock
Victoria L. Creamer, EVP and Chief People Officer of Charles River Laboratories, sold 4,179 shares at $259.16 each on Aug. 6, 2026. The sale was valued at…
Charles River reports Q2 loss, raises 2026 adjusted EPS and revenue outlook
Charles River reported second-quarter 2026 revenue of $1.00 billion for the period ended June 27, down 2.7% year over year, with a GAAP loss of $0.03 per…
Feb 25, 2026: $CRL agreed to sell its CDMO and Cell Solutions businesses to GI Partners for primarily…
Feb 25, 2026: $CRL agreed to sell its CDMO and Cell Solutions businesses to GI Partners for primarily contingent, performance‑based payments. Includes CDMO…
Charles River ($CRL) filed an 8-K (Item 9.01) on Feb 18, 2026 — Exhibits: 99.1 press release (dated Feb…
Charles River ($CRL) filed an 8-K (Item 9.01) on Feb 18, 2026 — Exhibits: 99.1 press release (dated Feb 18, 2026) and 104 iXBRL Cover Page. No financial…
Charles River ($CRL) 8‑K (Feb 18, 2026): issued press release with Q4 and FY results for period ended Dec…
Charles River ($CRL) 8‑K (Feb 18, 2026): issued press release with Q4 and FY results for period ended Dec 27, 2025; press release attached as an exhibit.…
Charles River ($CRL) filed an 8‑K (Item 9.01) disclosing an Employment Offer Letter with Glenn Coleman…
Charles River ($CRL) filed an 8‑K (Item 9.01) disclosing an Employment Offer Letter with Glenn Coleman dated Feb 12, 2026 (Exhibit 10.1). 8‑K signed Feb 18,…
Charles River names Glenn Coleman Corporate Executive VP & CFO, tentative start April 6, 2026.
Charles River names Glenn Coleman Corporate Executive VP & CFO, tentative start April 6, 2026. Coleman (58) brings 30+ yrs finance/ops experience incl. CFO…
Charles River ($CRL): Q4 DSA net book-to-bill ~1.1x as demand improved through H2 2025, led by small/mid…
Charles River ($CRL): Q4 DSA net book-to-bill ~1.1x as demand improved through H2 2025, led by small/mid biotech. Company expects organic revenue growth at…
Charles River ($CRL) presenting at J.P.
Charles River ($CRL) presenting at J.P. Morgan 44th Annual Healthcare Conf on Jan 13, 2026 ~1:30 PM ET — management to review strategy, business…
Charles River ($CRL): Board announces CEO/Chair transition — James C.
Charles River ($CRL): Board announces CEO/Chair transition — James C. Foster to step down as CEO & Chair; COO Birgit Girshick named CEO effective May 5,…